BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19014386)

  • 1. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
    Marti M; Trapella C; Morari M
    J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
    Marti M; Trapella C; Viaro R; Morari M
    J Neurosci; 2007 Feb; 27(6):1297-307. PubMed ID: 17287504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
    Mabrouk OS; Marti M; Morari M
    Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity.
    Volta M; Viaro R; Trapella C; Marti M; Morari M
    Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
    Mabrouk OS; Marti M; Salvadori S; Morari M
    Neuroscience; 2009 Dec; 164(2):360-9. PubMed ID: 19729051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).
    Volta M; Marti M; McDonald J; Molinari S; Camarda V; Pelà M; Trapella C; Morari M
    Peptides; 2010 Jun; 31(6):1194-204. PubMed ID: 20307605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
    Marti M; Mela F; Veronesi C; Guerrini R; Salvadori S; Federici M; Mercuri NB; Rizzi A; Franchi G; Beani L; Bianchi C; Morari M
    J Neurosci; 2004 Jul; 24(30):6659-66. PubMed ID: 15282268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism.
    Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M
    J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual motor response to l-dopa and nociceptin/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: Paradoxical inhibition is relieved by D(2)/D(3) receptor blockade.
    Viaro R; Marti M; Morari M
    Exp Neurol; 2010 Jun; 223(2):473-84. PubMed ID: 20122926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
    Mabrouk OS; Volta M; Marti M; Morari M
    J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    Marti M; Rodi D; Li Q; Guerrini R; Fasano S; Morella I; Tozzi A; Brambilla R; Calabresi P; Simonato M; Bezard E; Morari M
    J Neurosci; 2012 Nov; 32(46):16106-19. PubMed ID: 23152595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
    Volta M; Mabrouk OS; Bido S; Marti M; Morari M
    J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
    Brugnoli A; Pisanò CA; Morari M
    Neurobiol Dis; 2020 Oct; 144():105044. PubMed ID: 32798726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.
    Marti M; Mela F; Budri M; Volta M; Malfacini D; Molinari S; Zaveri NT; Ronzoni S; Petrillo P; Calò G; Morari M
    Br J Pharmacol; 2013 Feb; 168(4):863-79. PubMed ID: 22994368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release.
    Marti M; Mela F; Guerrini R; Calò G; Bianchi C; Morari M
    J Neurochem; 2004 Dec; 91(6):1501-4. PubMed ID: 15584926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.
    Arcuri L; Viaro R; Bido S; Longo F; Calcagno M; Fernagut PO; Zaveri NT; Calò G; Bezard E; Morari M
    Neurobiol Dis; 2016 May; 89():55-64. PubMed ID: 26804029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nociceptin/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat.
    Marti M; Guerrini R; Beani L; Bianchi C; Morari M
    Neuroscience; 2002; 112(1):153-60. PubMed ID: 12044480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the neuropeptide nociceptin/orphanin FQ in kainate seizures.
    Bregola G; Zucchini S; Rodi D; Binaschi A; D'Addario C; Landuzzi D; Reinscheid R; Candeletti S; Romualdi P; Simonato M
    J Neurosci; 2002 Nov; 22(22):10030-8. PubMed ID: 12427860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D; Conti MM; Ostock CY; George JA; Goldenberg AA; Melikhov-Sosin M; Nuss EE; Bishop C
    J Neurosci; 2016 Sep; 36(38):9873-87. PubMed ID: 27656025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.